AngioDynamics Stock Price and Value Analysis

AngioDynamics (NasdaqGS:ANGO) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

  • Ticker: ANGO (NasdaqGS)
  • Current price: $11.32
  • Sector: Unknown
  • Industry: Unknown

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold AngioDynamics to reach your target.

Target type

ANGO Free Cash Flow Trend

Free Cash Flow trendline for ANGO
Free Cash Flow trendline for AngioDynamics

Hmm, we can't give any reliable projection for AngioDynamics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is not making money.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the ANGO Numbers

ANGO Price
(AngioDynamics stock price per share)
$11.32
[?] PE Ratio versus Sector 60% lower than other Unknown stocks
[?] PE Ratio versus Industry 67% lower than other Unknown stocks
[?] Cash Yield 9.12%
[?] Free Cash Flow Jitter 132%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 2,003,326 shares shorted. With 32,758,314 shares available for purchase and an average trading volume over the past 10 trading days of 431,220, it would take at least 4.6 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 6 fiscal years from 2010 to 2026 with positive net income, operating cash flow totaled $233.0 million against net income of $105.4 million, or 2.21 times. Net income was negative in 11 of the 17 years, and those years are left out of the ratio.

In 2026, net income was -$36.7 million and operating cash flow was $3.1 million, so no ratio is shown for that year.

In 2026, capital expenditures were $2.6 million, 83.6% of operating cash flow of $3.1 million, which leaves an estimated $0.5 million after capex. Across the 13 years with reported capex, it averaged 18.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2010 12.3 40.0 5.0 3.25
2011 8.1 33.9 3.0 4.19
2012 -5.3 11.6 2.5 n/a
2013 -1.1 26.7 12.1 n/a
2014 2.3 24.7 11.2 10.52
2015 -3.4 25.7 11.4 n/a
2016 -43.6 45.2 2.3 n/a
2017 5.0 55.7 3.0 11.13
2018 16.3 41.3 2.4 2.53
2019 61.3 37.4 3.1 0.61
2020 -166.8 -14.6 7.2 n/a
2021 -31.5 24.1 5.2 n/a
2022 -26.5 -7.2 4.3 n/a
2023 -52.4 0.1 3.8 n/a
2024 -184.3 -28.2 2.5 n/a
2025 -34.0 -10.1 4.5 n/a
2026 -36.7 3.1 2.6 n/a

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 3 fiscal years from 2012 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $41.7 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 2 of the 3 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $15.7 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2012 8.1 n/a 2.1 2.1 26.0%
2017 47.7 n/a 13.6 13.6 28.4%
2025 -14.2 n/a 1.7 1.7 n/a

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $216.0 million in 2010 and $320.2 million in 2026, a compound annual growth rate of 2.5% over 16 years.

Revenue rose 9.5% from 2025 to 2026.

Our estimated free cash flow was -$0.4 million in 2026, a negative margin of 0.1% of revenue, meaning the estimate was below zero. In 2010 the estimated margin was 16.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2010 216.0 34.9 16.2%
2011 215.6 29.9 13.9%
2012 221.9 8.1 3.7%
2013 341.9 21.0 6.1%
2014 354.4 17.9 5.1%
2015 356.5 17.7 5.0%
2016 353.9 37.3 10.5%
2017 269.8 47.7 17.7%
2018 261.7 35.2 13.5%
2019 270.6 33.0 12.2%
2020 264.2 -18.2 -6.9%
2021 291.0 19.9 6.8%
2022 316.2 -11.6 -3.7%
2023 338.8 -4.7 -1.4%
2024 303.9 -32.8 -10.8%
2025 292.5 -14.2 -4.8%
2026 320.2 -0.4 -0.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2026, cash and equivalents were $53.9 million against total liabilities of $96.3 million, or 55.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 36.1% of total assets in 2026, compared with 7.3% in 2011, an increase of 28.8 percentage points.

Stockholders equity was $170.8 million in 2026, compared with $405.6 million in 2011, a fall of 57.9%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -0.3% in 2026. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2011 437.3 46.0 31.8 405.6
2012 719.9 23.7 196.6 523.3
2013 790.6 16.1 264.2 526.3
2014 798.6 18.4 261.7 536.9
2015 773.1 18.4 228.0 545.1
2016 726.2 32.3 219.0 507.2
2017 708.0 47.5 192.9 515.0
2018 705.5 74.1 162.9 542.6
2019 836.4 227.6 221.6 614.8
2020 594.2 54.4 139.3 454.9
2021 561.4 48.2 122.0 439.5
2022 552.8 28.8 128.3 424.5
2023 532.6 44.6 154.3 378.3
2024 317.7 76.1 112.1 205.6
2025 280.1 55.9 97.2 183.0
2026 267.2 53.9 96.3 170.8

Price Versus Our Estimated Value

We do not estimate a fair value for AngioDynamics while its free cash flow growth is not positive, so there is no value comparison here.

AngioDynamics reported positive free cash flow in 11 of the 17 fiscal years we have from its current SEC filer.

Free cash flow is volatile from year to year, with a variability measure of 132%.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

We do not have a dividend yield for AngioDynamics.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1275187.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 6 of the 17 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2026
Price and market data last refreshed
2026-11-18
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ANGO annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ANGO

Does AngioDynamics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ANGO

This example shows how we apply the Trendshare checklist to ANGO: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 11.32
    • Market cap: $476M
    • EPS: -0.78
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: 9.1%
    • Date checked: Nov 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.